Epamycetin250 mg

Epamycetin 250 mg is a broad-spectrum antibiotic used to treat a wide range of serious bacterial infections caused by susceptible organisms. Because it carries a risk of severe blood disorders, systemic (oral and injectable) Epamycetin 250 mg is generally reserved for serious or life-threatening infections in which safer antibiotics are ineffective, unavailable, or contraindicated. Topical forms (eye drops, eye ointment, and ear drops) are widely used for common superficial infections.

Systemic (Oral and Intravenous) Uses

• Typhoid and paratyphoid fever caused by Salmonella typhi and related species.
• Bacterial meningitis, particularly infections caused by Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae, often as an alternative in patients allergic to penicillins.
• Rickettsial infections, including typhus and Rocky Mountain spotted fever.
• Serious infections of the lymphogranuloma-psittacosis (chlamydial) group.
• Bacteraemia and severe Gram-negative infections where organisms are resistant to all other suitable antibiotics.
• Cholera and certain anaerobic infections, including brain abscess, as an alternative therapy.

Topical (Ophthalmic and Otic) Uses

• Bacterial conjunctivitis and other superficial infections of the eye (eye drops and eye ointment).
• Bacterial ear infections such as otitis externa (ear drops).
• Prophylaxis against infection following eye injury or surgery, when prescribed by a clinician.

Epamycetin 250 mg is included on the World Health Organization (WHO) List of Essential Medicines because of its effectiveness and low cost, and it remains an important treatment option in many parts of the world.

Epamycetin 250 mg belongs to the amphenicol group of antibiotics and is classified as a broad-spectrum antibacterial agent that works by inhibiting bacterial protein synthesis. It is effective against many Gram-positive bacteria, Gram-negative bacteria, anaerobes, rickettsiae, and chlamydiae. Epamycetin 250 mg is recognised on the World Health Organization (WHO) List of Essential Medicines and is available in systemic forms (oral capsules and intravenous injection) as well as topical forms (eye drops, eye ointment, and ear drops).

Epamycetin 250 mg is a broad-spectrum antibiotic originally isolated from Streptomyces venezuelae and now produced synthetically. It is active against many Gram-positive and Gram-negative bacteria, anaerobes, rickettsiae, and chlamydiae.

Mechanism of Action

Epamycetin 250 mg inhibits bacterial protein synthesis. It binds reversibly to the 50S subunit of the 70S bacterial ribosome and blocks the enzyme peptidyl transferase, preventing the formation of peptide bonds in the growing protein chain. This halts bacterial growth and reproduction.

The drug is primarily bacteriostatic (it stops bacteria from multiplying), but it can be bactericidal (it kills bacteria) at higher concentrations against certain organisms such as Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis.

Pharmacokinetics

• Absorption: Well absorbed after oral administration, with a bioavailability of at least 80%. The intravenous prodrug, Epamycetin 250 mg sodium succinate, is hydrolysed in the body to release active Epamycetin 250 mg.
• Distribution: Distributes widely throughout body tissues and fluids, including the cerebrospinal fluid (CSF), aqueous humour of the eye, and across the placenta. This wide penetration makes it useful in meningitis and eye infections.
• Metabolism: Metabolised mainly in the liver by conjugation with glucuronic acid to form inactive Epamycetin 250 mg glucuronide.
• Elimination: Excreted primarily in the urine, mostly as inactive metabolites. Because it is cleared by the liver, active drug does not accumulate significantly in patients with kidney impairment.
• Half-life: Approximately 1.5 to 4 hours in adults, but considerably longer in neonates and in patients with liver disease due to reduced metabolism.

Therapeutic drug monitoring may be used to keep peak serum levels within an effective and safe range (commonly 10–20 mcg/mL), as levels above 50 mcg/mL are associated with toxicity.

Epamycetin 250 mg inhibits certain liver enzymes (including CYP450) and can therefore alter the levels and effects of other medicines. Inform your doctor about all prescription drugs, over-the-counter products, and supplements you are taking.

Medicines Whose Effects May Be Increased

• Warfarin and other anticoagulants: Increased blood-thinning effect and risk of bleeding.
• Phenytoin: Raised phenytoin levels, increasing the risk of toxicity.
• Sulfonylureas (e.g., glibenclamide, tolbutamide): Enhanced blood-glucose-lowering effect, raising the risk of hypoglycaemia.
• Other drugs metabolised by the liver may have prolonged or intensified effects.

Medicines That May Reduce Epamycetin 250 mg Levels

• Phenobarbital and rifampicin (rifampin): May lower Epamycetin 250 mg blood levels and reduce its effectiveness.

Antibiotic and Vaccine Interactions

• Penicillins and cephalosporins: Epamycetin 250 mg may antagonise the bactericidal action of these antibiotics if used together.
• Macrolides and lincosamides (e.g., erythromycin, clindamycin): These bind to a similar ribosomal site and may compete with Epamycetin 250 mg.
• Live bacterial vaccines (e.g., oral typhoid vaccine): Epamycetin 250 mg may reduce vaccine effectiveness; the vaccine should be delayed until treatment is complete.

Effect on Anaemia Treatment

• Epamycetin 250 mg may reduce the response to iron, vitamin B12, and folic acid used to treat anaemia, because it can suppress bone marrow activity.

Like all medicines, Epamycetin 250 mg can cause side effects, though not everyone experiences them. The most serious effects involve the blood and bone marrow and are the main reason systemic use is restricted.

Serious Side Effects

• Aplastic anaemia: A rare but potentially fatal failure of the bone marrow. It is idiosyncratic (not dose-related), cannot be predicted, and may develop weeks or months after treatment has stopped.
• Dose-related bone marrow suppression: A reversible decrease in red blood cells, white blood cells, and platelets, more likely with high doses or prolonged treatment.
• Gray baby syndrome: A serious reaction in newborns and premature infants involving vomiting, poor feeding, low body temperature, a grey-blue skin colour, floppiness, and circulatory collapse (see Special Populations).
• Severe allergic reactions: Including angioedema, urticaria, and, rarely, anaphylaxis.

Common and Less Serious Side Effects

• Nausea, vomiting, diarrhoea, and abdominal discomfort.
• Inflammation of the mouth or tongue (stomatitis, glossitis).
• Headache, mild depression, or mental confusion.
• Skin rashes, itching, and fever.

Effects With Prolonged Use

• Optic neuritis (inflammation of the optic nerve, which can affect vision) and peripheral neuritis (nerve pain or numbness in the hands and feet), usually reversible if the drug is stopped promptly.

Side Effects of Eye and Ear Preparations

• Temporary stinging, burning, itching, or blurred vision after application.
• Local irritation or, rarely, an allergic reaction. Serious blood disorders from topical use are extremely rare.

Seek medical attention urgently if you notice unusual bleeding or bruising, sore throat with fever, extreme tiredness, or vision changes, as these may signal a serious blood or nerve problem. This information does not cover all possible side effects; consult a healthcare professional for personalised advice.

Pregnancy

Epamycetin 250 mg crosses the placenta, and fetal blood levels can approach those in the mother. It has been assigned Pregnancy Category C (risk cannot be ruled out). Although it is not known to cause birth defects, its use near the end of pregnancy and during labour is of particular concern because it may cause gray baby syndrome in the newborn. Epamycetin 250 mg should be used during pregnancy only if clearly needed, when the potential benefit justifies the potential risk, and when safer alternatives are unsuitable. Use in the third trimester should be avoided where possible.

Breastfeeding (Lactation)

Epamycetin 250 mg passes into breast milk. Although milk levels are usually not high enough to cause gray baby syndrome, there is a theoretical risk of bone marrow suppression, and because Epamycetin 250 mg-related aplastic anaemia is not dose-related, this cannot be entirely excluded. Reported effects in breastfed infants include vomiting, excessive wind, and drowsiness at the breast. An alternative antibiotic is generally preferred while breastfeeding, especially when nursing a newborn or premature infant. If systemic Epamycetin 250 mg is essential, the infant should be monitored, and stopping breastfeeding may sometimes be advised.

Topical eye and ear preparations result in very low systemic absorption and are generally considered lower risk, but they should still be used under medical guidance during pregnancy and breastfeeding.

Because of the risk of serious blood disorders, Epamycetin 250 mg requires careful use and close supervision.

• Reserve for serious infections: Systemic Epamycetin 250 mg should only be used when less toxic antibiotics are ineffective or unsuitable, and should never be used for minor infections or prophylaxis.
• Blood monitoring: A baseline complete blood count should be taken before treatment, with regular blood tests during therapy. However, monitoring cannot reliably predict or prevent idiosyncratic aplastic anaemia.
• Avoid repeated courses: Repeated or prolonged courses increase the risk of bone marrow toxicity and should be avoided.
• Liver and kidney impairment: Use with caution and reduce the dose, as impaired metabolism or excretion can lead to drug accumulation and toxicity.
• Neonates and infants: Extreme caution is required because of the risk of gray baby syndrome; doses must be reduced and blood levels monitored.
• G6PD deficiency: Patients with glucose-6-phosphate dehydrogenase deficiency may be at increased risk of red blood cell breakdown (haemolysis).
• Prolonged use: Watch for signs of optic or peripheral neuritis, particularly with long courses, and stop treatment if they occur.
• Superinfection: As with other antibiotics, prolonged use may lead to overgrowth of non-susceptible organisms, including fungi.
• Contact lenses: Do not wear contact lenses while using Epamycetin 250 mg eye drops or ointment, and while the eye is infected.
• Driving: If eye preparations cause temporary blurred vision, wait until your sight is clear before driving or operating machinery.

Overdosage of Epamycetin 250 mg, or excessively high blood levels, can cause serious toxicity. Symptoms may include:

• Bone marrow suppression, leading to anaemia, low white cell counts, and low platelets.
• In adults with very high blood levels, a syndrome similar to gray baby syndrome, with low blood pressure, metabolic acidosis, pale or grey skin, low body temperature, and circulatory collapse.
• Nausea, vomiting, and general unwellness.

Management

There is no specific antidote. Treatment is mainly supportive: Epamycetin 250 mg should be stopped immediately, and vital functions supported. In severe overdose, procedures such as charcoal haemoperfusion, haemodialysis, or exchange transfusion (particularly in neonates) may help remove the drug from the body. Blood counts should be monitored closely. If an overdose is suspected, seek emergency medical care or contact a poison control centre without delay.

• Capsules and oral forms: Store in a cool, dry place below 25°C, protected from light and moisture.
• Injection (powder for reconstitution): Store as directed on the label, usually below 25°C. Once reconstituted, use within the time specified by the manufacturer.
• Eye drops: Many Epamycetin 250 mg eye drops should be stored in a refrigerator (2–8°C). Once opened, discard after the period stated on the label, commonly 4 weeks.
• Eye ointment and ear drops: Store at room temperature, away from direct heat and light, unless the label states otherwise.
• Keep all medicines out of the sight and reach of children.
• Do not use after the expiry date printed on the packaging, and return any unused medicine to a pharmacy for safe disposal.

Neonates and Infants

Newborns, especially premature infants, have an immature liver that cannot efficiently break down Epamycetin 250 mg. This can cause the drug to accumulate to toxic levels, leading to gray baby syndrome. If treatment is unavoidable, the dose should not exceed 25 mg/kg/day initially, and it must be guided by blood-level monitoring.

Children

Epamycetin 250 mg may be used in older infants and children for serious infections such as meningitis, at 50 mg/kg/day in divided doses, increased only when necessary and with careful monitoring. Epamycetin 250 mg eye drops and ointment are not recommended for children under 2 years of age without medical advice.

Elderly Patients

Elderly patients can usually receive the standard adult dose, provided their liver and kidney function are normal. Careful monitoring is advisable, as reduced organ function is more common with age.

Patients with Liver Impairment

Since Epamycetin 250 mg is metabolised mainly by the liver, impaired liver function can cause the drug to accumulate. Dose reduction and blood-level monitoring are recommended.

Patients with Kidney Impairment

Active Epamycetin 250 mg does not accumulate substantially in kidney impairment because it is cleared by the liver; however, its inactive metabolites may build up. Caution and monitoring are still advised.